15.33
+0.63(+4.29%)
Currency In USD
| Previous Close | 14.7 |
| Open | 14.58 |
| Day High | 15.43 |
| Day Low | 14.2 |
| 52-Week High | 19.11 |
| 52-Week Low | 3.91 |
| Volume | 1.06M |
| Average Volume | 1.12M |
| Market Cap | 1.27B |
| PE | -5.11 |
| EPS | -3 |
| Moving Average 50 Days | 15.89 |
| Moving Average 200 Days | 12.05 |
| Change | 0.63 |
If you invested $1000 in EyePoint Pharmaceuticals, Inc. (EYPT) 10 years ago, it would be worth $547.5 as of February 21, 2026 at a share price of $15.33. Whereas If you bought $1000 worth of EyePoint Pharmaceuticals, Inc. (EYPT) shares 5 years ago, it would be worth $1,292.58 as of February 21, 2026 at a share price of $15.33.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
EyePoint Appoints Michael Campbell as Chief Commercial Officer
GlobeNewswire Inc.
Feb 18, 2026 12:00 PM GMT
– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma –– Brings established track record of successful product launches and oversight of prominent ophthalmology franchises, including Lucen
EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 05, 2026 12:00 PM GMT
WATERTOWN, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Ge
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
GlobeNewswire Inc.
Jan 07, 2026 12:00 PM GMT
– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 – – Phase 3 DME program first patient dosing ex